Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.65
DRRX's Cash to Debt is ranked lower than
56% of the 778 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. DRRX: 1.65 )
Ranked among companies with meaningful Cash to Debt only.
DRRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.63  Med: 21.46 Max: No Debt
Current: 1.65
Equity to Asset 0.38
DRRX's Equity to Asset is ranked lower than
81% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. DRRX: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
DRRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.45 Max: 0.96
Current: 0.38
0.07
0.96
F-Score: 2
Z-Score: -7.87
M-Score: -2.89
WACC vs ROIC
12.83%
-495.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -162.63
DRRX's Operating margin (%) is ranked lower than
90% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.44 vs. DRRX: -162.63 )
Ranked among companies with meaningful Operating margin (%) only.
DRRX' s Operating margin (%) Range Over the Past 10 Years
Min: -164.81  Med: -108.14 Max: 30.25
Current: -162.63
-164.81
30.25
Net-margin (%) -175.10
DRRX's Net-margin (%) is ranked lower than
90% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. DRRX: -175.10 )
Ranked among companies with meaningful Net-margin (%) only.
DRRX' s Net-margin (%) Range Over the Past 10 Years
Min: -175.1  Med: -116.24 Max: 30.53
Current: -175.1
-175.1
30.53
ROE (%) -173.08
DRRX's ROE (%) is ranked lower than
96% of the 753 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.76 vs. DRRX: -173.08 )
Ranked among companies with meaningful ROE (%) only.
DRRX' s ROE (%) Range Over the Past 10 Years
Min: -208.92  Med: -91.21 Max: 81.39
Current: -173.08
-208.92
81.39
ROA (%) -60.87
DRRX's ROA (%) is ranked lower than
92% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. DRRX: -60.87 )
Ranked among companies with meaningful ROA (%) only.
DRRX' s ROA (%) Range Over the Past 10 Years
Min: -60.87  Med: -40.99 Max: 34.06
Current: -60.87
-60.87
34.06
ROC (Joel Greenblatt) (%) -901.12
DRRX's ROC (Joel Greenblatt) (%) is ranked lower than
90% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.07 vs. DRRX: -901.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DRRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -977.57  Med: -686.89 Max: 500.45
Current: -901.12
-977.57
500.45
Revenue Growth (3Y)(%) -35.50
DRRX's Revenue Growth (3Y)(%) is ranked lower than
94% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. DRRX: -35.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DRRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.5  Med: 5.85 Max: 234
Current: -35.5
-35.5
234
» DRRX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-02)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

DRRX Guru Trades in Q3 2015

First Eagle Investment 14,081,446 sh (+6.71%)
Jim Simons 206,800 sh (-8.94%)
Robert Bruce 763,609 sh (-11.58%)
» More
Q4 2015

DRRX Guru Trades in Q4 2015

First Eagle Investment 14,081,446 sh (unchged)
Robert Bruce 713,609 sh (-6.55%)
Jim Simons 139,000 sh (-32.79%)
» More
Q1 2016

DRRX Guru Trades in Q1 2016

First Eagle Investment 14,381,546 sh (+2.13%)
Robert Bruce 713,609 sh (unchged)
Jim Simons Sold Out
» More
Q2 2016

DRRX Guru Trades in Q2 2016

First Eagle Investment 19,881,546 sh (+38.24%)
Robert Bruce 713,609 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with DRRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:SNDX, NAS:AQXP, NAS:AGRX, OTCPK:ORXOY, OTCPK:SCLRF, OTCPK:APHQF, OTCPK:TWMJF, OTCPK:SENZ, NAS:RIGL, NAS:TTPH, OTCPK:ACBFF, NAS:BPTH, NAS:KPTI, NAS:MSLI, OTCPK:ELTP, NAS:ARLZ, NAS:ZYNE, NAS:NEOS, NAS:PSDV, NAS:SMMT » details
Traded in other countries:DC8.Germany,
Durect Corp is a specialty pharmaceutical company. It develops pharmaceutical products based on its proprietary drug delivery technology platforms.

Durect Corp was incorporated in Delaware in February 1998. The Company is a biopharmaceutical company engaged in the development of pharmaceutical products based on its proprietary drug delivery technology platforms. The Company's product pipeline currently consists of seven investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).The Company has other programs underway in fields outside of pain management, including several efforts underway which seek to improve the administration of biotechnology agents such as proteins and peptides. The Company's development efforts are focused on the application of its pharmaceutical systems technologies to potential products in a variety of chronic and episodic disease areas including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases. Its product candidate include Remoxy (Oral controlled release oxycodone); POSIDUR (Controlled release injection of bupivacaine); ELADUR (Transdermal bupivacaine); TRANSDUR-Sufentanil (Transdermal sufentanil); ORADUR-based opioid (hydrocodone); ORADUR-based opioid (hydromorphone); ORADUR-ADHD; ORADUR-based opioid (oxymorphone); and Relday (risperidone). Its pharmaceutical systems enable optimized therapy for a given disease or patient population by controlling the rate and duration of drug administration. The Company has several technology platforms: Bioerodible Injectable Depot Systems, The TRANSDUR Transdermal Delivery System, The ORADUR Sustained Release Gel Cap Technology, and The DURIN Biodegradable Implant Technology. POSIDUR, SABER, CLOUD, TRANSDUR, ORADUR, ELADUR, DURIN, CHRONOGESIC, MICRODUR, ALZET and LACTEL are the trademarks of the Company. The manufacturing and marketing of its pharmaceutical systems and its research and development activities are subject to extensive regulation for safety, efficacy and quality by numerous government authorities in the United States and abroad.

Ratios

vs
industry
vs
history
P/B 10.00
DRRX's P/B is ranked lower than
93% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. DRRX: 10.00 )
Ranked among companies with meaningful P/B only.
DRRX' s P/B Range Over the Past 10 Years
Min: 1.68  Med: 8.36 Max: 39.79
Current: 10
1.68
39.79
P/S 10.22
DRRX's P/S is ranked lower than
85% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. DRRX: 10.22 )
Ranked among companies with meaningful P/S only.
DRRX' s P/S Range Over the Past 10 Years
Min: 0.91  Med: 8.84 Max: 20.84
Current: 10.22
0.91
20.84
Current Ratio 5.37
DRRX's Current Ratio is ranked higher than
79% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. DRRX: 5.37 )
Ranked among companies with meaningful Current Ratio only.
DRRX' s Current Ratio Range Over the Past 10 Years
Min: 1.48  Med: 5.69 Max: 29.59
Current: 5.37
1.48
29.59
Quick Ratio 4.83
DRRX's Quick Ratio is ranked higher than
79% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. DRRX: 4.83 )
Ranked among companies with meaningful Quick Ratio only.
DRRX' s Quick Ratio Range Over the Past 10 Years
Min: 1.41  Med: 5.26 Max: 28.73
Current: 4.83
1.41
28.73
Days Inventory 361.78
DRRX's Days Inventory is ranked lower than
94% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.00 vs. DRRX: 361.78 )
Ranked among companies with meaningful Days Inventory only.
DRRX' s Days Inventory Range Over the Past 10 Years
Min: 215.56  Med: 238.15 Max: 361.78
Current: 361.78
215.56
361.78
Days Sales Outstanding 40.60
DRRX's Days Sales Outstanding is ranked higher than
79% of the 579 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.08 vs. DRRX: 40.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
DRRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.9  Med: 41.17 Max: 55.94
Current: 40.6
14.9
55.94
Days Payable 119.22
DRRX's Days Payable is ranked higher than
78% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.81 vs. DRRX: 119.22 )
Ranked among companies with meaningful Days Payable only.
DRRX' s Days Payable Range Over the Past 10 Years
Min: 55.54  Med: 97.88 Max: 207.57
Current: 119.22
55.54
207.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.10
DRRX's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. DRRX: -6.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DRRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.5  Med: -7.35 Max: -2.1
Current: -6.1
-28.5
-2.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 140.00
DRRX's Price/Net Cash is ranked lower than
95% of the 201 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.90 vs. DRRX: 140.00 )
Ranked among companies with meaningful Price/Net Cash only.
DRRX' s Price/Net Cash Range Over the Past 10 Years
Min: 2.33  Med: 17.45 Max: 525
Current: 140
2.33
525
Price/Net Current Asset Value 20.00
DRRX's Price/Net Current Asset Value is ranked lower than
85% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.54 vs. DRRX: 20.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DRRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.03  Med: 11.93 Max: 172.5
Current: 20
2.03
172.5
Price/Tangible Book 15.56
DRRX's Price/Tangible Book is ranked lower than
93% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. DRRX: 15.56 )
Ranked among companies with meaningful Price/Tangible Book only.
DRRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.37  Med: 8.08 Max: 184.55
Current: 15.56
1.37
184.55
Price/Median PS Value 1.16
DRRX's Price/Median PS Value is ranked lower than
63% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. DRRX: 1.16 )
Ranked among companies with meaningful Price/Median PS Value only.
DRRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 1.23 Max: 10.56
Current: 1.16
0.12
10.56
Earnings Yield (Greenblatt) (%) -15.01
DRRX's Earnings Yield (Greenblatt) (%) is ranked lower than
86% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. DRRX: -15.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DRRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -18.39  Med: 30.1 Max: 48.9
Current: -15.01
-18.39
48.9

More Statistics

Revenue (TTM) (Mil) $16.68
EPS (TTM) $ -0.23
Beta1.51
Short Percentage of Float3.30%
52-Week Range $0.99 - 2.70
Shares Outstanding (Mil)137.41

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 13 17 14
EPS ($) -0.26 -0.23 -0.15
EPS w/o NRI ($) -0.26 -0.23 -0.15
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for DRRX

Headlines

Articles On GuruFocus.com
Jean-Marie Eveillard and Arnold Van Den Berg Raise Stakes in Small-Cap Stocks Mar 24 2015 
Jean-Marie Eveillard Ups Stake in Pharma Company Durect Mar 23 2015 
Durect Corp. Reports Operating Results (10-Q) Nov 04 2010 
Durect Corp. Reports Operating Results (10-Q) Aug 05 2010 
Opportunistic Coat-tailing Jan 05 2010 
Durect Corp. Reports Operating Results (10-Q) Nov 02 2009 
Durect Corp. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
ETF’s with exposure to DURECT Corp. : September 27, 2016 Sep 27 2016
Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection Sep 26 2016
DURECT CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 26 2016
5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy Sep 26 2016
GW Pharmaceuticals (GWPH), Sally Beauty Holdings Inc. (SBH) & More: Why These Stocks Are Making... Sep 26 2016
Pain Therapeutics receives FDA letter saying NDA for opioid analgesic can't be approved Sep 26 2016
7:06 am Durect announces its licensee Pain Therapeutics (PTIE)... Sep 26 2016
DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER... Sep 26 2016
ETF’s with exposure to DURECT Corp. : September 14, 2016 Sep 14 2016
The Life Sciences Report Examines Three Shots on Goal in Q4/16 for DURECT Corp. Sep 09 2016
DURECT to Present at the Rodman & Renshaw Global Investment Conference Sep 06 2016
ETF’s with exposure to DURECT Corp. : August 29, 2016 Aug 29 2016
Edited Transcript of DRRX earnings conference call or presentation 1-Aug-16 8:30pm GMT Aug 16 2016
DURECT CORP Files SEC form 8-K, Change in Directors or Principal Officers Aug 09 2016
DURECT CORP Financials Aug 09 2016
ETF’s with exposure to DURECT Corp. : August 8, 2016 Aug 08 2016
DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 Aug 05 2016
DURECT CORP Files SEC form 10-Q, Quarterly Report Aug 02 2016
DRRX: Update on Second Quarter Financials Aug 02 2016
Durect reports 2Q loss Aug 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)